Shanghai Haohai Biological Technology Co., Ltd.

Sümbol: 6826.HK

HKSE

42.45

HKD

Turuhind täna

15.1027
P/E suhe
0.7575
PEG suhe
16.43B
MRK Cap
0.01%
DIV tootlus

Shanghai Haohai Biological Technology Co., Ltd. (6826-HK) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Shanghai Haohai Biological Technology Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014
balance-sheet.row.cash-and-short-term-investments	2751.1	2541.7	2907.2	3107.7	3222.5	1438.4	1797.4	2010.3	2177.8	181.3
balance-sheet.row.short-term-investments	11.1	6.7	6.4	15.1	16.5	81.3	0	9.1	140	21.3
balance-sheet.row.net-receivables	447.6	471.1	375.2	340.7	390	81.3	0	0	140	83.8
balance-sheet.row.inventory	526.2	485.2	354.8	255.1	240	197.6	174.9	118	78.1	76.4
balance-sheet.row.other-current-assets	25.2	34.1	69.6	116.8	76.4	576.6	413.6	360	-23.8	5.8
balance-sheet.row.total-current-assets	3750.1	3532.1	3712.6	3810	3945.4	2293.9	2386	2488.2	2372.1	347.4
balance-sheet.row.property-plant-equipment-net	1553	1409.6	1248.9	1041.7	1111.8	734.7	652.7	483.8	399.4	362.7
balance-sheet.row.goodwill	413	411.2	406.9	385.5	333.5	332	410.1	292.1	0	0
balance-sheet.row.intangible-assets	729.1	783.5	783.1	578.9	430.6	467.1	490.2	326.3	34.9	36.4
balance-sheet.row.goodwill-and-intangible-assets	1142.1	1194.7	1190	964.4	764.1	799.1	900.3	618.4	34.9	36.4
balance-sheet.row.long-term-investments	596	664.7	619	440.4	298	510.3	108.8	55.1	-128.8	-10.7
balance-sheet.row.tax-assets	53.1	59.3	49.4	26.2	18.4	17	17.5	8.8	4.4	5.5
balance-sheet.row.other-non-current-assets	11.1	32	130.5	16.1	14.3	81.3	10	39.1	140	10.7
balance-sheet.row.total-non-current-assets	3355.4	3360.3	3237.8	2488.7	2206.5	2142.5	1689.3	1205.2	449.9	404.5
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	7105.5	6892.4	6950.4	6298.7	6151.9	4436.4	4075.3	3693.4	2821.9	751.9
balance-sheet.row.account-payables	55.1	54.5	46.3	28	36.8	41.2	39	19.7	4.8	8.8
balance-sheet.row.short-term-debt	216.6	34.4	66	87.7	25.7	20.3	19.9	26.7	0	0
balance-sheet.row.tax-payables	58.4	52.1	17.8	32.9	46.6	50.9	63.1	86.3	38.5	34.9
balance-sheet.row.long-term-debt-total	191.3	83.9	39.5	20.4	24	16.4	17.6	0	0	0
Deferred Revenue Non Current	13.6	5.5	9.4	3.5	3.6	6.2	9.1	12	14.9	17.7
balance-sheet.row.deferred-tax-liabilities-non-current	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	444.2	422.4	375	318	297.5	389.9	418.9	442.5	136.2	130.4
balance-sheet.row.total-non-current-liabilities	372.3	478.7	402.8	130.7	138.6	149.6	230.8	171.4	15.5	18.5
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	54.2	61.3	46.7	28.7	34.4	0	0	0	0	0
balance-sheet.row.total-liab	1088.2	990	890.1	564.5	498.5	600.9	708.6	707.6	156.5	157.7
balance-sheet.row.preferred-stock	71.7	47	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	171.5	174.1	175.8	177.2	177.8	160	160	160	160	120
balance-sheet.row.retained-earnings	2728.6	2369.5	2309.7	2046.1	1846.6	1557.9	1178.8	894.8	671.5	417.8
balance-sheet.row.accumulated-other-comprehensive-income-loss	-71.7	-47	47.9	35.9	59.5	-225.3	-179.4	-146.2	-115.6	-83.3
balance-sheet.row.other-total-stockholders-equity	2750	2971	3180	3231.5	3370.8	2118.8	2207.3	2077.2	1949.5	139.6
balance-sheet.row.total-stockholders-equity	5650.1	5514.6	5713.5	5490.8	5454.8	3611.5	3200.6	2904	2661.9	594.2
balance-sheet.row.total-liabilities-and-stockholders-equity	7105.5	6892.4	6950.4	6298.7	6151.9	4436.4	4075.3	3693.4	2821.9	751.9
balance-sheet.row.minority-interest	367.2	387.8	346.8	243.5	198.6	223.9	166.1	81.9	3.5	0
balance-sheet.row.total-equity	6017.3	5902.4	6060.3	5734.2	5653.4	3835.4	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	-	-	-	-	-	-	-	-	-	-
Total Investments	607.1	671.4	625.3	455.5	298	591.6	108.8	64.2	11.2	21.3
balance-sheet.row.total-debt	407.9	118.3	105.5	108.1	49.7	36.7	37.5	26.7	0	0
balance-sheet.row.net-debt	-2332.1	-2423.5	-2795.3	-2984.5	-3172.8	-1401.8	-1759.9	-1983.6	-2177.8	-181.3

Rahavoogude aruanne

Shanghai Haohai Biological Technology Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014
cash-flows.row.net-income	508.3	235.7	382.6	257	434.3	525.2	461.6	365.9	320.6	215.6
cash-flows.row.depreciation-and-amortization	197.9	204.2	162.8	132.9	115.4	83.6	67.7	35.8	34	22.8
cash-flows.row.deferred-income-tax	-81.6	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	14.3	30.2	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	73.2	-183.5	23.9	66.9	-40.5	-41.1	-47.1	-58.1	-16.9	-53.9
cash-flows.row.account-receivables	0	-52.3	-41.9	15.6	-18.9	0	0	0	0	0
cash-flows.row.inventory	-48.4	-138.9	-28.6	-18.7	-27.9	-23.2	-47.3	9.7	-1.7	-33.8
cash-flows.row.account-payables	0	52.3	41.9	-15.6	18.9	0	0	0	0	0
cash-flows.row.other-working-capital	121.6	-44.6	52.6	85.6	-12.6	-17.9	0.2	-67.9	-15.2	-20.2
cash-flows.row.other-non-cash-items	-77.6	-55.4	-227.1	-194.7	-160.4	-176.4	-139.2	-89.1	-69.3	-42.5
cash-flows.row.net-cash-provided-by-operating-activities	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-267.2	-317.1	-272.1	-195.9	-399.3	-151.9	-134.7	-75.7	-70.1	-93.6
cash-flows.row.acquisitions-net	1.6	14.7	-83.3	-88.4	-57.1	-433.8	-337.4	-246.4	-7.7	0
cash-flows.row.purchases-of-investments	-204.2	-528.8	-696.6	-273.9	-1302.5	-281.6	-80.2	-1210.8	-118.7	-0.7
cash-flows.row.sales-maturities-of-investments	14.6	9.1	749.3	649.3	166.3	433.1	382.4	4.5	38.3	0
cash-flows.row.other-investing-activites	78.6	140.4	154.6	225.8	456.8	-360.5	21.6	17.1	8.9	6.2
cash-flows.row.net-cash-used-for-investing-activites	-376.6	-681.8	-148.1	316.9	-1135.7	-794.6	-148.4	-1511.2	-149.3	-88.2
cash-flows.row.debt-repayment	-16.4	-47.9	-95.5	-49.9	-79.5	-42.3	-27.1	-4.8	0	0
cash-flows.row.common-stock-issued	73.7	0	-4	84.8	1539.1	0	0	0	1863.7	0
cash-flows.row.common-stock-repurchased	-270	-147.7	-44.9	-51	0	0	0	0	0	0
cash-flows.row.dividends-paid	-68.5	-121.9	-87.9	-124	-80	-80	-85.8	-58.6	-49.7	-70.3
cash-flows.row.other-financing-activites	-245.7	29.1	1.1	-50	13	37	16.4	5	-59.5	0
cash-flows.row.net-cash-used-provided-by-financing-activities	-257.7	-288.4	-231.3	-190.1	1392.5	-85.3	-96.5	-58.4	1754.6	-70.3
cash-flows.row.effect-of-forex-changes-on-cash	10	14.2	-6.9	-5.6	3.2	2.4	-1.6	2.6	4	0
cash-flows.row.net-change-in-cash	10.1	-724.7	-44	383.4	608.9	-486.3	96.6	-1312.5	1877.8	-16.5
cash-flows.row.cash-at-end-of-period	569.3	559.2	1283.9	1327.9	944.5	335.6	821.9	725.3	2037.8	160
cash-flows.row.cash-at-beginning-of-period	559.2	1283.9	1327.9	944.5	335.6	821.9	725.3	2037.8	160	176.5
cash-flows.row.operating-cash-flow	634.5	231.3	342.3	262.1	348.9	391.3	343.1	254.5	268.5	142
cash-flows.row.capital-expenditure	-267.2	-317.1	-272.1	-195.9	-399.3	-151.9	-134.7	-75.7	-70.1	-93.6
cash-flows.row.free-cash-flow	367.2	-85.9	70.2	66.2	-50.4	239.4	208.3	178.8	198.4	48.4

Kasumiaruande rida

Shanghai Haohai Biological Technology Co., Ltd. tulud muutusid võrreldes eelmise perioodiga NaN%. 6826.HK brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014
income-statement-row.row.total-revenue	2634.9	2103.4	1750.1	1324.4	1595.5	1545.8	1344.9	851.2	663.9	515.9
income-statement-row.row.cost-of-revenue	781.4	656.5	490.4	334	364	334.3	287.5	141.6	105.1	65.9
income-statement-row.row.gross-profit	1853.5	1446.9	1259.7	990.4	1231.5	1211.5	1057.4	709.6	558.8	450.1
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-4	-40.3	-33.9	-33.9	107.7	0.3	-16.3	-5.4	0.6	-1.6
income-statement-row.row.operating-expenses	1415.1	1226.8	1032.2	865.1	929.2	768.4	641.9	399.6	306.2	236.9
income-statement-row.row.cost-and-expenses	2196.5	1883.3	1522.5	1199.1	1293.2	1102.7	929.3	541.1	411.2	302.8
income-statement-row.row.interest-income	77.7	87.9	98.2	108.5	66.6	59.1	59.5	58.5	38.3	3.7
income-statement-row.row.interest-expense	7.3	7.6	5	4.9	4.5	2.1	2.2	0.2	0	0
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-4.7	-22.9	-1.8	-3.5	-3.6	82.1	46.1	55.8	68	2.5
income-statement-row.row.ebitda-ratio-caps	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-4	-40.3	-33.9	-33.9	107.7	0.3	-16.3	-5.4	0.6	-1.6
income-statement-row.row.total-operating-expenses	-4.7	-22.9	-1.8	-3.5	-3.6	82.1	46.1	55.8	68	2.5
income-statement-row.row.interest-expense	7.3	7.6	5	4.9	4.5	2.1	2.2	0.2	0	0
income-statement-row.row.depreciation-and-amortization	197.9	204.2	162.8	132.9	115.4	83.6	67.7	35.8	34	22.8
income-statement-row.row.ebitda-caps	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	513	258.7	384.4	260.6	438	443.1	415.5	372.9	321.4	218.2
income-statement-row.row.income-before-tax	508.3	235.7	382.6	257	434.3	525.2	461.6	365.9	320.6	215.6
income-statement-row.row.income-tax-expense	96	45.4	35.4	30.7	58	70.1	61.6	55.3	47.3	32
income-statement-row.row.net-income	416.1	180.5	352.2	230.1	370.8	414.5	372.4	305.1	273.5	183.6